Pfizer commits $800,000 to EyeCare America program
December 5th 2006New York-Pfizer Ophthalmics has awarded an $800,000 grant to EyeCare America’s Glaucoma EyeCare Program, which promotes the early detection and treatment of glaucoma by raising awareness of risk factors and providing free access to glaucoma eye exams. The grant will support the program for 2 years.
Allergan announces Horizon Grant recipients
December 5th 2006Irvine, CA-Allergan Inc. has announced the recipients of its first Allergan Horizon Grant Program awards. The company will contribute $1 million over 2 years to academic medical institutions to support fellows conducting clinical research in the diagnosis or pharmacologic treatment of glaucoma and corneal and retinal diseases.
Transpupillary thermotherapy has high success rate with choroidal melanomas
December 1st 2006Rochester, MN-Transpupillary thermotherapy (TTT) caused small choroidal melanoma tumors to regress in most of the patients who were treated with this diode laser therapy. In a study of 40 patients, almost 80% of patients were successfully treated with one application of TTT. Additional therapy with TTT and other modalities was needed to treat some cases of small choroidal melanomas.
Resident surgery-when the problem is the attending
December 1st 2006I recall a case during residency when I was chopping quadrants of a dense cataract in a short eye with poor dilation and pseudoexfoliation. For medical reasons, the anesthesiologist kept the sedation light. That, combined with topical anesthesia, made this patient very awake and very able to move his eye all over the field.
VEGF Trap undergoing global development
December 1st 2006Leverkusen, Germany, and Tarrytown, NY-Bayer Healthcare and Regeneron Pharmaceuticals Inc. have entered into a collaboration agreement for the global development of the vascular endothelial growth factor (VEGF) Trap for possible treatment of the neovascular form of age-related macular degeneration (AMD), diabetic eye diseases, and other eye diseases and disorders.
Care for post-PK patients key to graft survival
December 1st 2006Grand Rapids, MI-Just as the preoperative evaluation of patients about to undergo corneal transplantations involves numerous factors, so does the postoperative management of patients who have undergone these procedures, especially penetrating keratoplasty (PK). David D. Verdier, MD, outlined how to care for these patients with special emphasis on corneal surface problems, which he believes are responsible for a high percentage of graft failures.
Single-dose azithromycin reduces recurrences after trichiasis surgery
December 1st 2006Baltimore-Results of a prospective randomized trial conducted in Ethiopia demonstrated that a single dose of oral azithromycin (Zithromax, Pfizer) after trichiasis surgery safely and significantly reduced trichiasis recurrence compared with a 6-week course of topical treatment with tetracycline ointment, reported Sheila K. West, PhD, and colleagues.
Stage IV DLK prognosis excellent with new approach to therapy
December 1st 2006Loma Linda, CA-Recovery of full visual function is possible in eyes with stage IV diffuse lamellar keratitis (DLK) using a novel management paradigm that is based on a new pathophysiologic model of the disorder, said Brian R. Will, MD, assistant clinical professor of ophthalmology, Loma Linda University School of Medicine, Loma Linda, CA.
2006 saw the fine-tuning of existing technologies
December 1st 2006New options for patients, such as multifocal IOLs; refinements in surgery, such as Descemet's stripping automated endothelial keratopathy (DSAEK); and encouraging results from technology in the pipeline, such as intracorneal inlays, which would provide another new avenue for patients with presbyopia; as well as high marks received by the femtosecond laser (IntraLase FS, IntraLase Corp.) for cutting flaps-these are but a few of the refractive surgery high points of 2006 cited by ophthalmic surgeons.
Eli Lily debates potential DR treatment
December 1st 2006Indianapolis, IN-Eli Lilly and Co. said it is "weighing its options" regarding further development of ruboxistaurin mesylate after the FDA requested an additional 3-year, phase III clinical trial of the molecule that could treat severe nonproliferative diabetic retinopathy.
'Food Dude' to deliver Manus C. Kraff lecture
December 1st 2006San Diego-A world-renowned authority on the role of nutrition and lifestyle in the prevention of disease will deliver the Manus C. Kraff Lecture on Science and Medicine at the 2007 Symposium of the American Society of Cataract and Refractive Surgery in April.
VEGF Trap undergoing global development
December 1st 2006Leverkusen, Germany, and Tarrytown, NY-Bayer Healthcare and Regeneron Pharmaceuticals Inc. have entered into a collaboration agreement for the global development of the vascular endothelial growth factor (VEGF) Trap for possible treatment of the neovascular form of age-related macular degeneration (AMD), diabetic eye diseases, and other eye diseases and disorders.
TargeGen initiates trial of topical AMD drug
December 1st 2006San Diego-TargeGen Inc. has initiated a single-site phase I clinical trial involving TG100801, a small molecule, topically applied multi-targeted kinase inhibitor for the treatment of age-related macular degeneration (AMD) and other debilitating diseases of the eye.
FDA approves ketotifen eye drop
December 1st 2006East Hanover, NJ-The FDA has approved the over-the-counter (OTC) use of ketotifen fumarate ophthalmic solution 0.025% (Zaditor) for the temporary prevention of itchy eyes due to allergic conjunctivitis. The drops treat eye itch associated with pollen, ragweed, grass, animal hair, and dander without the potentially negative effects of a decongestant.
Vitamin A deficiency returns to an unsuspecting audience
December 1st 2006Houston-Intestinal surgeries-such as gastric bypass, resections of the large and small bowel, and gallbladder removal-may interfere with the intestine's ability to absorb vitamin A, resulting in the potential for severe deficiencies and compromised vision.
Operating microscope offers 'lightless cataract surgery'
December 1st 2006London-A new operating microscope for cataract surgery that uses near-infrared light to illuminate the surgical field offers several advantages compared with the conventional microscope, including possible faster visual recovery and the potential to avoid phototoxic retinopathy.